Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes
详细信息 查看全文
- 作者：Morten A. Karsdal ; Kim Henriksen ; Federica Genovese ; Diana J. Leeming…
- 关键词：Balaglitazone ; Efficacy ; PPARγ ; Safety ; Type 2 diabetes
- 刊名：Diabetologia
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：60
- 期：1
- 页码：50-59
- 全文大小：491KB
- 刊物类别：Medicine
- 刊物主题：Internal Medicine; Metabolic Diseases; Human Physiology;
- 出版者：Springer Berlin Heidelberg
- ISSN：1432-0428
- 卷排序：60
文摘
Aims/hypothesisThe treatment of type 2 diabetes with full peroxisome proliferator-activated receptor gamma (PPARγ) agonists improves insulin sensitivity, but is associated with weight gain, heart failure, peripheral oedema and bone loss. Endotrophin, the C-terminal fragment of the α3 chain of procollagen type VI (also called Pro-C6), is involved in both adipose tissue matrix remodelling and metabolic control. We established a serum assay for endotrophin to assess if this novel adipokine could identify type 2 diabetic patients who respond optimally to PPARγ agonists, improving the risk-to-benefit ratio.